The IQMH office is closed to prevent the spread of COVID-19. We have moved to a virtual office. More info: IQMH Response to COVID-19.



Get industry news and event information sent to your inbox.
Job Ad Posting Service





One week to go! The IQMH Fall Forum 2019 - Register

By Editor on 10/29/2019


Use code: special20 to get a 20% discount.

Allied Health Professional Development Fund
Ontario medical laboratory technologists and medical radiation technologists can apply for reimbursement of conference registration fees through the Allied Health Professional Development Fund. Each professional can claim up to $1500 per year. Learn more:

Click to download print-friendly PDF.


 Jeff Sumner

Bill Roberts
Master of Ceremonies

Jeff Sumner
CEO and President at IQMH



Ron Booth

Dr. Ron Booth
Associate Professor in the Department of Pathology and Laboratory Medicine at the University of Ottawa and Clinical Biochemist at the Ottawa Hospital

Cancer-associated antibody syndromes: optic nerve (head) to peripheral neuropathy (toe) review

Paraneoplastic conditions are defined as clinical syndromes involving non-metastatic systemic effects that accompany malignant disease. In many cases, the paraneoplastic effects are mediated by autoantibodies generated by the immune response against the malignant tissue. Various cancer-associated antibody mediated syndromes will be reviewed.


 Aaron Pollett

Dr. Aaron Pollett
Anatomic Pathologist and co-director of the Division of Diagnostic Medical Genetics at Mount Sinai Hospital 

Acting on Cancer Pathology Information: Bringing Synoptic Data to Life

Synoptic reporting of pathology allows for pathology information to be captured as discrete data elements. Having information is this extractable manner supports quality initiatives, and with the introduction of synoptic biomarker reporting can be used to direct patient care. This presentation will outline the current state of synoptic cancer reporting in Ontario. It will show how synoptic reporting has supported a number of quality improvement projects. Current and future quality initiatives involving synoptic reporting will be described along with the future applications for synoptic molecular biomarker reporting.


BREAK 10:15–10:45

 Amir Rajab

Amr Rajab
Flow cytometry Technical Specialist at LifeLabs

Utilization of Screening Tubes in Flow Cytometry Diagnostic Settings

Clinical laboratories face increasing demands for flow cytometry services and limited budget. Amr Rajab will highlight the advantages of using screening tubes in clinical flow Cytometry testing of hematolymphoid malignancies.


 Denise Heaney

Dr. Denise Heaney
Senior Scientific Affairs Manager in Medical and Scientific Affairs supporting the Diagnostics Information Solutions Division, Roche Diagnostics

The Emerging Role of Digital Diagnostics in Precision Medicine: Harnessing Data to Transform Patient Care

Digital healthcare is about collecting vast amounts of data from a variety of sources, from medical records to clinical trials to population health and analyzing it to impact patient care and outcomes. This presentation will focus on the ways digital diagnostics is harnessing data to transform patient care through clinical decision support.


LUNCH 12:15–13:45  |  Product Highlight: Roche Diagnostics — NAVIFY Tumor Board presented by Dan Tiber

David Good

Dr. David Good
Service Chief for Hematopathology at Kingston Health Sciences Centre and an Assistant Professor in the Department of Pathology and Molecular Medicine at Queen’s University

Advances in the Diagnosis of Myeloid Neoplasms

Recent technological advances, including targeted next-generation sequencing (NGS) panels, have permitted the identification of several genes recurrently mutated in myeloid malignancies with expanding diagnostic and clinical significance. A diagnostic testing algorithm has been implemented at Kingston Health Sciences Centre for acute leukemia and selected MDS and MPN cases.


 Meredith Irwin

Dr. Meredith Irwin
Associate Chair Pediatrics (Research) Head, Solid Tumor Section, Division of Hematology-Oncology, The Hospital for Sick Children

Innovations in Pediatric Oncology: Little patients, big impact and challenges

The cure rates for pediatric cancer now exceed 80%; however, for patients with metastatic or relapsed disease survival is dismal. With new technologies including whole exome, genome, and RNA sequencing novel alterations can be identified. In the Sick Kids and national KICS and PROFYLE programs children with relapsed and hard to treat cancers currently have access to these comprehensive sequencing technologies, which have identified actionable genomic alterations in patients’ tumors and germline, providing information that can impact the diagnosis, prognosis, genetic risk for cancer, and in a subset, identify a tumor-specific target for therapy.


Dr. Scott Boerner
Cytopathologist, University Health Network Laboratory Medicine Program

Sylvie Grenier
Senior Technologist, Genome Diagnostics Laboratory at the University Health Network

Waste Not, Want Not.  Extracting Big Data From Surprising Places

Sample availability is critical for the many downstream histochemical, molecular and cytogenetic applications. We propose the use of cytology samples as a potential resource for clinical molecular tests of various tumour types. We will present two ongoing projects that compares next-generation sequencing (NGS) results from previously validated samples and matched cytological preparations and suggest future directions towards utilizing cytology samples for clinical molecular tests.






 David Huntsman

Leslee Thompson
CEO Accreditation Canada and Health Standards Organization (HSO)


Dr. David Huntsman
Professor in the Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology at The University of British Columbia and Founder of Contextual Genomics

Digital pathology, genomics and cell free DNA testing: new ways of helping patients and studying cancer



 Karim Bhaloo

Karim Bhaloo
Technologist, Cancer Cytogenetics Laboratory, University Health Network

The Multiple Myeloma Mystery

A patient sample was received for multiple myeloma (MM) testing. The sample was magnetically separated (MS) and tested positive for MM. The patient was tested again six months later for a pre-clinical trial screening. The sample was once again MS for MM testing, but this time was negative for all rearrangements despite the fact that the patient had received no treatment and still had MM.


BREAK 10:00–10:30

 Malcolm Kendall

Dr. Malcolm Kendall
CEO and Cofounder of Microbiome Insights

The Human Microbiome and Cancer Diagnosis, Treatment and Prevention...Inconceivable, or Not?


 Jennifer Mitchell

Dr. Jennifer Mitchell
Associate Professor at the University of Toronto, Department of Cell and Systems Biology

CRISPR Technologies: The Path to New Cancer Treatments and Precision Diagnosis

CRISPR technologies revolutionized fundamental research and have the potential to treat genetic diseases. In the context of cancer, genome-wide CRISPR screens have the revealed essentiality genes for different cancer types determining the drugs that could most effectively treat different cancers. Furthermore, CRISPR has been used to create Chimeric antigen receptor (CAR) T cells that target cancer cells expressing specific surface markers. Precision cancer treatment requires precision diagnosis to determine the appropriate treatment.


LUNCH 12:00–13:30 | Product Highlight: BD Canada — The impact of standardized flow assay on leukemia and lymphoma diagnostics presented by Lori Apoll and Sylvain Gimmig 

 Joan Murphy

Dr. Joan Murphy
Clinical Lead, Ontario Cervical Screening Program

Re-Thinking Cervical Screening in Ontario

As the landscape of cervical screening evolves, including the significant impact of HPV immunization, the implementation of HPV testing becomes more relevant to continue to improve cervical screening and help prevent cervical cancer in our population. Cancer Care Ontario (in time Ontario Health) and the Ministry of Health are working to implement HPV testing in cervical screening and colposcopy to ensure that Ontarians continue to receive the best evidence-based care. Implementing HPV testing is a large multi-year initiative, and this presentation will provide an overview of key aspects of this work.


Patient Panel

Randall Conrad, Melissa Gomes, Debbie Kerr, Hannah Senitt,
Ashley Farrelly

Invaluable Insight from Patients

Four patients will provide their cancer story and discuss their specific experience with medical laboratory: 

  • The waiting
  • The complexity of information and the use of patient portals
  • Benefits and drawbacks to patient access to laboratory results
  • Pokes and prods
  • What can we do better?
  • Why patient stories are important


Centre for Education
Centre for Education
IQMH Fall Forum 2019


Institute for Quality
Management in Healthcare

1500-393 University Avenue
Toronto, Ontario Canada M5G 1E6





Get industry news and event information:SUBSCRIBE

Terms Of Use Privacy Statement © Copyright 2020 IQMH.